Biomind Labs Inc.
BMND
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 45.07% | 64.12% | 163.32% | 72.53% | 41.26% |
| Total Depreciation and Amortization | -100.00% | 0.00% | -- | 0.00% | -73.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -76.81% | -164.11% | -278.05% | -1,780.00% | 6,368.75% |
| Change in Net Operating Assets | 38.18% | 1,720.00% | 95.06% | -126.26% | -56.67% |
| Cash from Operations | 178.17% | 100.43% | 51.12% | 18.49% | 84.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -99.48% | -- | -19.94% | -75.60% | -51.16% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.48% | -- | -20.69% | -77.83% | -50.79% |
| Foreign Exchange rate Adjustments | 6.13% | -112.82% | 633.33% | 253.91% | -140.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 100.75% | -100.00% | 90.45% | -133.92% | -128.42% |